ClinicalTrials.gg
RecruitingNCT04979338Updated Sep 17, 2025

Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries

A Phase 3 interventional study of Ultrasound guided Continuous Infraclavicular Brachial Plexus Block and Ultrasound guided Continuous Femoral Nerve Block in Gender Dysphoria, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Cedars-Sinai Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Gender Dysphoria with a site in United States — 11 open to participants now, 13 under way, 3 of them phase 3. Gender Dysphoria · United States.

Planned enrollment
2nd of 15
640 · median 50
Started
2021
with 2 others
Phase 3
2 of 31
2 open now
Primary completion
2026-09
later than 3 of 12 live
Registered
13th of 31
by date
Lead sponsor
1 of 31
Cedars-Sinai Medical Center

Among the 31 studies in Gender Dysphoria with a site in United States, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 2 in phase 3, reaches primary completion later than 3 of the 12 other live ones, and was the 13th registered.

Gender Dysphoria

85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.

Browse Gender Dysphoria studies →

Open to participants now

11 of the 31 studies in Gender Dysphoria with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Gender Dysphoria with a site in United States, or all of them as a file.
02

Study summary

This study will compare the current standard-of-care pain treatment regimen options that are available to patients who undergo gender-affirming surgery. The purpose of this research is to determine if any of these options are more (versus less) effective than the others to manage surgery related pain, after surgery.

03

Conditions studied

  • Gender Dysphoria

Browse trials for

Keywords

  • Gender Dysphoria
  • Gender-Affirming Surgery
  • Peri-Operative Pain
  • Pain Management
  • Surgery Pain
  • Sex Reassignment Surgery
  • Gender Reassignment Surgery
  • Vaginoplasty
  • Phalloplasty
  • Quality Improvement
  • Opioid Use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Transgender persons 18 years and older
  • Undergoing gender affirming surgeries performed by either Dr. Maurice Garcia (orchiectomy only, vaginoplasty with or without canal \& orchiectomy, colon-vaginoplasty, \& peritoneal vaginoplasty; Stage I phalloplasty, or stage II phalloplasty); Dr. Edward Ray (feminizing chest surgery, masculinizing chest surgery, stage I phalloplasty); Dr. Amit Gupta (orchiectomy and peritoneal vaginoplasty only); or Dr. Yosef Nasseri (colon vaginoplasty surgery)

Exclusion criteria

Exclusion Criteria:

  • Patients who do not meet the inclusion criteria above
  • Any to the study drugs.
  • Patients with neurologic deficits that preclude them from sensing pain.
  • Patients with implanted pain neuromodulator devices (e.g., neurostimulator)
  • Patients who do not speak English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants (estimated)

Study arms

  • Active comparator
    Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #1

    Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the pre-incision, intra-op, mid-surgery, end of surgery, or continuous time points: * Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord) * Local anesthetic (0.25% or 0.5% bupivacaine + 1:200K epinephrine) * Bilateral ultrasound guided pudendal nerve block (20-40 cc of 0.25% bupivacaine + 1:200K epinephrine) * Ultrasound guided Continuous Infraclavicular Brachial Plexus Block * Ultrasound guided Continuous Femoral Nerve Block * Pecs I \& II Block (0.25% bupivacaine: 15-30ml per side for Pecs I-III)

    Other: Ultrasound guided Continuous Infraclavicular Brachial Plexus Block · Other: Ultrasound guided Continuous Femoral Nerve Block · Other: Ultrasound guided Pudendal Nerve Block · Drug: Bupivacaine · Other: Bilateral spermatic cord block · Other: Pecs I & II Block · Other: Local anesthetic

  • Active comparator
    Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #2

    Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the intra-op, post-op, or end of surgery time points: * Bilateral ultrasound-guided Transversus Abdominis Plane Block (40-60cc of 0.25% bupivacaine with 1:200K epinephrine) * Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)

    Drug: Bupivacaine · Other: Bilateral ultrasound guided Transversus Abdominis Plane Block · Other: Local anesthetic

  • Active comparator
    Surgery-specific general anesthetic + local anesthetic at incision site

    Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the mid-surgery or end of surgery time points: * Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord) * Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)

    Drug: Bupivacaine · Other: Bilateral spermatic cord block · Other: Local anesthetic

Interventions

  • OtherUltrasound guided Continuous Infraclavicular Brachial Plexus Block

    20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]

  • OtherUltrasound guided Continuous Femoral Nerve Block

    20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]

  • OtherUltrasound guided Pudendal Nerve Block

    20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]

  • 0.25% or 0.5% with or without 1:200K epinephrine

    Also known as: Marcaine

  • OtherBilateral ultrasound guided Transversus Abdominis Plane Block

    40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]

  • OtherBilateral spermatic cord block

    10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]

  • OtherPecs I & II Block

    0.25% bupivacaine: 15-30mL per side for Pecs I-III

  • OtherLocal anesthetic

    0.25% or 0.5% bupivacaine into the appropriate surgical site

06

What researchers measure

Primary outcomes

  1. Changes in peri-operative pain location and intensity over time, as measured by anatomic pain maps

    Anterior and posterior illustrations of the body, with pre-defined areas involved in surgery that may be circled, will be used to define pain location. Pain scores for each circled area will be measured on a Likert-scale between 0-10, with 0 indicating no pain and 10 indicating the worst pain experienced in respondent's life.

    Time frame: Any time pain is experienced, starting on the morning of post-operative Day 1 to End of Study at the final post-operative visit (average of 30 days after surgery)

  2. Changes in opioid consumption per 24 hours, measured by total inpatient and total outpatient

    Inpatient opioid consumption will be obtained from hospital records. Outpatient opioid consumption will be determined from completed medication logs. Opioid consumption will be measured per 24 hours, by hospital location (e.g., PACU versus Ward), and by post-operative day.

    Time frame: Per 24 hours, starting on post-operative Day 1 to End of Study at the final post-operative visit (average of 30 days after surgery)

  3. Change in the opioid side effect of urinary retention, as indicated by time to spontaneous voiding

    Recorded time to spontaneous voiding will be collected from hospital records.

    Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)

  4. Change in the opioid side effect of urinary retention, as measured by a Urinary Bother Symptom Score Questionnaire

    A Urinary Bother Symptom Score Questionnaire, obtained from the American Urological Association, will assess the frequency of different urinary problems, such as incomplete emptying, intermittency, and urgency. Each urinary problem will be measured on a scale from 0 to 5, with 0 indicating "none/not at all" and 5 indicating "almost always."

    Time frame: Pre-operative visit, Discharge (average of 7 days after surgery), and End of Study/final post-operative visit (average of 30 days after surgery)

  5. Change in the opioid side effect of decreased GI motility and ileus, as indicated by number of post-operative days until commencement of regular passage of flatus

    Recorded number of post-operative days until commencement of regular passage of flatus will be obtained from hospital records.

    Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)

  6. Change in the opioid side effect of nausea, as indicated by number of post-operative days to toleration of liquid diet and regular diet, as well as reported experience of nausea

    Recorded number of post-operative days and experience of nausea will be obtained from hospital records.

    Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)

  7. Post-operative length of inpatient stay

    Length of inpatient stay will be obtained from hospital records as the recorded number of days spent inpatient after surgery

    Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)

  8. Global satisfaction with respect to pain and physical comfort, as measured by a Quality of Recovery 15-Item Inventory

    Questions 1-10 will assess global well-being and physical comfort, such as ability to return to work or usual home activities, feeling rested, ability to enjoy food, and general feelings of well-being. These questions will be rated on a scale of 0 to 10, with 0 indicating none of the time (poor) and 10 indicating all of the time (excellent). Questions 11-15 will assess pain and physical comfort, such as presence of moderate/severe pain, nausea or vomiting, worried or anxious feelings, and sad or depressed feelings. These questions will be rated on a scale of 0 to 10, with 0 indicating all of the time (poor) and 10 indicating none of the time (excellent).

    Time frame: Daily, starting on the morning of post-operative Day 1 to End of Study at the final post-operative visit (average of 30 days after surgery)

  9. Frequency of treatment complications

    Treatment complications, such as hematoma, infection, etc., will only include those that are determined to be related to the study treatment.

    Time frame: End of study (average of 30 days after surgery)

Secondary outcomes

  1. Time to mobilization

    The recorded number of days to mobilization will be obtained from hospital records.

    Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)

  2. Time to first day of bowel movement

    The recorded number of days to first bowel movement will be obtained from hospital records.

    Time frame: Post-operative Day 1 to Discharge (average of 7 days after surgery)

  3. Number of participants with any hospital readmission within 30 days of discharge

    Time frame: 30 days after Day of Discharge (average of 7 days after surgery)

07

Study locations

1 of 1 sites recruiting
  • Cedars-Sinai Medical Center - North and South Towers
    Los Angeles, California 90048, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Sep 2026, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2021
First posted
Jul 28, 2021
StartActual
Nov 11, 2021
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04979338
Responsible party
Maurice M. Garcia (Director of the Cedars-Sinai Transgender Surgery and Health Program, Cedars-Sinai Medical Center) — Principal investigator
First posted
Jul 28, 2021
Start date
Nov 11, 2021
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Jenna Stelmar, BS
Contact
jenna.stelmar@cshs.org
805-813-7882
Maurice M Garcia, M.D., MAS
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion